(LQDA) Liquidia Technologies - Overview
Stock: Treprostinil, Inhaled, Injectable, Liposomal, PAH
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 60.7% |
| Relative Tail Risk | -12.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.78 |
| Alpha | 156.42 |
| Character TTM | |
|---|---|
| Beta | 1.119 |
| Beta Downside | 1.097 |
| Drawdowns 3y | |
|---|---|
| Max DD | 46.80% |
| CAGR/Max DD | 1.82 |
Description: LQDA Liquidia Technologies January 15, 2026
Liquidia Technologies (NASDAQ:LQDA) is a U.S.-based biopharma that focuses on developing, manufacturing, and commercializing treprostinil-based therapies for unmet needs in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its lead candidates are YUTREPIA (inhaled dry-powder treprostinil) and L606, a liposomal formulation currently in Phase III trials, while it also markets Remodulin, an IV/subcutaneous treprostinil infusion. The company holds a development and commercialization license with Pharmosa Biopharm for an inhaled sustained-release version of treprostinil.
Key external metrics (as of the latest Q2 2024 filing) suggest a market opportunity of roughly $5 billion for PAH/PH-ILD therapies, with an estimated CAGR of 6-7 % driven by aging demographics and expanding diagnostic rates. Liquidia reported cash and equivalents of $112 million, a quarterly burn of $28 million, and a net loss of $45 million, indicating a runway of about 12-15 months absent additional financing. The company’s pipeline valuation is highly sensitive to the upcoming FDA decision on YUTREPIA (expected Q3 2024) and Phase III readout for L606 (anticipated early 2025); a positive outcome could lift its enterprise value by 30-40 % based on comparable peer multiples.
For analysts looking to deepen their assessment, a quick review of ValueRay’s detailed cash-flow and scenario analysis for LQDA may uncover additional upside or downside risks worth exploring.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -121.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.39 > 0.02 and ΔFCF/TA -2.51 > 1.0 |
| NWC/Revenue: 178.8% < 20% (prev 1156 %; Δ -976.7% < -1%) |
| CFO/TA -0.37 > 3% & CFO -100.7m > Net Income -121.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (86.3m) vs 12m ago 10.24% < -2% |
| Gross Margin: 89.40% > 18% (prev 0.63%; Δ 8877 % > 0.5%) |
| Asset Turnover: 26.18% > 50% (prev 6.17%; Δ 20.00% > 0%) |
| Interest Coverage Ratio: -4.63 > 6 (EBITDA TTM -98.5m / Interest Expense TTM 21.6m) |
Altman Z'' -9.82
| A: 0.45 (Total Current Assets 226.7m - Total Current Liabilities 102.9m) / Total Assets 276.0m |
| B: -2.32 (Retained Earnings -640.9m / Total Assets 276.0m) |
| C: -0.38 (EBIT TTM -100.2m / Avg Total Assets 264.4m) |
| D: -2.52 (Book Value of Equity -640.8m / Total Liabilities 253.9m) |
| Altman-Z'' Score: -9.82 = D |
Beneish M -0.10
| DSRI: 1.93 (Receivables 36.0m/4.20m, Revenue 69.2m/15.6m) |
| GMI: 0.70 (GM 89.40% / 62.80%) |
| AQI: 1.07 (AQ_t 0.13 / AQ_t-1 0.12) |
| SGI: 4.43 (Revenue 69.2m / 15.6m) |
| TATA: -0.08 (NI -121.8m - CFO -100.7m) / TA 276.0m) |
| Beneish M-Score: -0.10 (Cap -4..+1) = D |
What is the price of LQDA shares?
Over the past week, the price has changed by +1.53%, over one month by +40.10%, over three months by +68.12% and over the past year by +169.67%.
Is LQDA a buy, sell or hold?
- StrongBuy: 6
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the LQDA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 43 | -0.1% |
| Analysts Target Price | 43 | -0.1% |
| ValueRay Target Price | 74.3 | 72.7% |
LQDA Fundamental Data Overview February 03, 2026
P/S = 53.2787
P/B = 169.8724
Revenue TTM = 69.2m USD
EBIT TTM = -100.2m USD
EBITDA TTM = -98.5m USD
Long Term Debt = 136.4m USD (from longTermDebt, last quarter)
Short Term Debt = 56.9m USD (from shortTermDebt, last quarter)
Debt = 199.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 41.7m USD (from netDebt column, last quarter)
Enterprise Value = 3.73b USD (3.69b + Debt 199.2m - CCE 157.5m)
Interest Coverage Ratio = -4.63 (Ebit TTM -100.2m / Interest Expense TTM 21.6m)
EV/FCF = -34.59x (Enterprise Value 3.73b / FCF TTM -107.8m)
FCF Yield = -2.89% (FCF TTM -107.8m / Enterprise Value 3.73b)
FCF Margin = -155.8% (FCF TTM -107.8m / Revenue TTM 69.2m)
Net Margin = -176.0% (Net Income TTM -121.8m / Revenue TTM 69.2m)
Gross Margin = 89.40% ((Revenue TTM 69.2m - Cost of Revenue TTM 7.34m) / Revenue TTM)
Gross Margin QoQ = 94.16% (prev 85.38%)
Tobins Q-Ratio = 13.51 (Enterprise Value 3.73b / Total Assets 276.0m)
Interest Expense / Debt = 3.49% (Interest Expense 6.95m / Debt 199.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -79.2m (EBIT -100.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.20 (Total Current Assets 226.7m / Total Current Liabilities 102.9m)
Debt / Equity = 9.03 (Debt 199.2m / totalStockholderEquity, last quarter 22.1m)
Debt / EBITDA = -0.42 (negative EBITDA) (Net Debt 41.7m / EBITDA -98.5m)
Debt / FCF = -0.39 (negative FCF - burning cash) (Net Debt 41.7m / FCF TTM -107.8m)
Total Stockholder Equity = 41.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -46.08% (Net Income -121.8m / Total Assets 276.0m)
RoE = -296.8% (Net Income TTM -121.8m / Total Stockholder Equity 41.1m)
RoCE = -56.45% (EBIT -100.2m / Capital Employed (Equity 41.1m + L.T.Debt 136.4m))
RoIC = -39.26% (negative operating profit) (NOPAT -79.2m / Invested Capital 201.6m)
WACC = 9.67% (E(3.69b)/V(3.89b) * Re(10.04%) + D(199.2m)/V(3.89b) * Rd(3.49%) * (1-Tc(0.21)))
Discount Rate = 10.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.66%
Fair Price DCF = unknown (Cash Flow -107.8m)
EPS Correlation: -14.25 | EPS CAGR: 21.86% | SUE: -1.08 | # QB: 0
Revenue Correlation: 43.87 | Revenue CAGR: 112.5% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.43 | Chg30d=+0.207 | Revisions Net=+0 | Analysts=4
EPS next Year (2026-12-31): EPS=2.69 | Chg30d=+0.587 | Revisions Net=+0 | Growth EPS=+496.2% | Growth Revenue=+219.2%